Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., … Sharma, P. (2015). Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 373(19), 1803–1813. https://doi.org/10.1056/nejmoa1510665

Motzer, Robert J., Bernard Escudier, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, et al. “Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.” New England Journal of Medicine 373, no. 19 (November 5, 2015): 1803–13. https://doi.org/10.1056/nejmoa1510665.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 2015 Nov 5;373(19):1803–13.

Motzer, Robert J., et al. “Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.” New England Journal of Medicine, vol. 373, no. 19, Massachusetts Medical Society, Nov. 2015, pp. 1803–13. Crossref, doi:10.1056/nejmoa1510665.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu L-A, Waxman IM, Sharma P. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine. Massachusetts Medical Society; 2015 Nov 5;373(19):1803–1813.